Microbiome and human health: current understanding, engineering, and enabling technologies
The human microbiome is composed of a collection of dynamic microbial communities that
inhabit various anatomical locations in the body. Accordingly, the coevolution of the …
inhabit various anatomical locations in the body. Accordingly, the coevolution of the …
Next-generation sequencing: insights to advance clinical investigations of the microbiome
CR Wensel, JL Pluznick, SL Salzberg… - The Journal of clinical …, 2022 - Am Soc Clin Investig
Next-generation sequencing (NGS) technology has advanced our understanding of the
human microbiome by allowing for the discovery and characterization of unculturable …
human microbiome by allowing for the discovery and characterization of unculturable …
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
P Feuerstadt, TJ Louie, B Lashner… - … England Journal of …, 2022 - Mass Medical Soc
Background Current therapies for recurrent Clostridioides difficile infection do not address
the disrupted microbiome, which supports C. difficile spore germination into toxin-producing …
the disrupted microbiome, which supports C. difficile spore germination into toxin-producing …
Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed
MS Butler, V Gigante, H Sati, S Paulin… - Antimicrobial agents …, 2022 - Am Soc Microbiol
There is an urgent global need for new strategies and drugs to control and treat multidrug-
resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of …
resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of …
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Despite the promising advances in novel cancer therapy such as immune checkpoint
inhibitors (ICIs), limitations including therapeutic resistance and toxicity remain. In recent …
inhibitors (ICIs), limitations including therapeutic resistance and toxicity remain. In recent …
[HTML][HTML] 2021 antibacterial agents in clinical and preclinical development: an overview and analysis
World Health Organization - 2022 - books.google.com
Page 1 2021 ANTIBACTERIAL AGENTS IN CLINICAL AND PRECLINICAL DEVELOPMENT:
an overview and analysis World Health Organization Page 2 A PRE Page 3 2021 …
an overview and analysis World Health Organization Page 2 A PRE Page 3 2021 …
Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single …
Importance A safe and effective treatment for recurrentClostridioides difficileinfection (CDI) is
urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted …
urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted …
[HTML][HTML] Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers
Manipulation of the gut microbiota via fecal microbiota transplantation (FMT) has shown
clinical promise in diseases such as recurrent Clostridioides difficile infection (rCDI) …
clinical promise in diseases such as recurrent Clostridioides difficile infection (rCDI) …
Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications
Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated
infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as …
infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as …
Pathogenicity and virulence of Clostridioides difficile
Clostridioides difficile is the most common cause of nosocomial antibiotic-associated
diarrhea, and is responsible for a spectrum of diseases characterized by high levels of …
diarrhea, and is responsible for a spectrum of diseases characterized by high levels of …